Key result
Type 1 diabetes is linked to ~27% higher serum sRAGE levels vs healthy controls.
Case-Control (n=80)
Answers are grounded in this paper and cite their sources.
To the Editor: The hyperglycemic state occurring in diabetes mellitus is responsible for formation and accumulation of advanced glycation endproducts (AGEs) that participate in the pathogenesis of vascular complications of diabetes mellitus (1). There is considerable interest in the receptors for AGEs (RAGE) found in many cell types, particularly those affected in diabetes. RAGE are members of the immunoglobulin family of cell surface molecules with a diverse repertoire of ligands. Interaction of AGEs with RAGE alters several cell functions through modulation of intracellular signaling, gene expression, and release of proinflammatory molecules and free radicals that contribute to the pathology of diabetic complications (2)(3). A soluble form of RAGE (sRAGE) can be measured in peripheral blood, which could result from the expression of a RAGE splice gene variant that encodes an amino-terminally truncated form of the receptor and/or from the cleavage of the native membranous receptor (4). This form may be released by several cell types, such as endothelial cells and circulating leukocytes. Because sRAGE is presumed to be a decoy for RAGE ligands and thus to have cytoprotective properties against AGE actions, we measured circulating sRAGE concentrations in patients with type 1 diabetes and compared it with values for nondiabetic controls. We collected blood samples from 45 patients with type 1 diabetes [mean (SD) age, 40 (5) years; range, 23–75 years]. Patients with macrovascular complications of diabetes mellitus (clinical evidence or history of coronary artery disease), nephropathy (urinary albumin excretion >30 mg/24 h), or peripheral neuropathy, as well as those with known hepatic or rheumatoid disease, recent acute illness, alcoholism, or treatment with antiinflammatory medications were not included. Nine diabetic patients presented with moderate to severe retinopathy [classification of the French Association for The Study of Diabetes and Metabolic Diseases (ALFEDIAM) (5)], as assessed by direct ophthalmoscopy through dilated pupils. A control group of healthy persons [n = 35; mean (SD) age, 43 (10) years; range, 25–63 years] was also recruited. On the day of the clinical examination, blood samples were taken by venipuncture after a 12-h overnight fast. Glycohemoglobin (Hb A1c) was measured by an HPLC method (Tosoh); the reference interval for this assay was 4.0%–5.6%. High-sensitivity C-reactive protein (hsCRP) was measured with an immunonephelometric assay on a BNII analyzer (Dade-Behring). Serum concentrations of sRAGE were measured by the Quantikine RAGE enzyme-linked immunoassay (R&D Systems). Intraassay CVs were <7%, and between-assay CVs were <9%. Statistical analysis was carried out with the nonparametric Mann–Whitney test; P values <0.05 were considered statistically significant. The results of these analyses are shown in Table 11 . Mean (SD) values for serum RAGE were significantly higher in patients with type 1 diabetes than in nondiabetic controls [1320 (459) and 1041 (392) ng/L, respectively; P <0.001]. Median values were similarly different between the two groups: 1343 and 953 ng/L, respectively, for patients with type 1 diabetes and controls (P <0.001). Circulating concentrations of sRAGE were also significantly higher in patients with type 1 diabetes with moderate/severe retinopathy than in controls (Table 11 ); however, values for diabetic patients with ocular complications did not differ significantly from the values for patients free of retinopathy. Finally, we found no associations between circulating concentrations of sRAGE and duration of diabetes (r = −0.31), Hb A1c concentrations (r = −0.169), or hsCRP concentrations (r = −0.228; not significant for all three). Substantial evidence supports a role for AGE/RAGE interactions in the pathophysiology of diabetes. Accumulation of RAGE ligands, as occurs in the diabetic state, leads to enhancement of cellular expression of the receptor, thereby triggering cell dysfunction. Little is known about the regulatory aspects of RAGE and sRAGE gene expression; we can presume that in diabetes mellitus, increased formation of AGEs, which are positive regulators of cell expression of RAGE, enhances secretion of sRAGE in a similar manner. On the other hand, the lack of association between sRAGE concentrations and Hb A1c values or diabetes duration is unexpected because these two variables have been shown to correlate with AGEs (6). The observed increase in sRAGE in diabetic patients, however, can be viewed as a protective reaction to counterbalance, at least partly, the increase in AGE formation in these patients. Recently, Falcone et al. (7) reported low concentrations of sRAGE in plasma in nondiabetic patients with coronary artery disease. This result does not disagree with ours, if we consider that the soluble isoform of RAGE could play an antagonistic role by competing with the cell-surface receptor. However, the pathophysiologic mechanisms that are responsible for the increase in circulating concentrations of sRAGE in diabetes or its decrease in coronary artery disease remain to be clarified. Finally, although our cohort of patients with retinopathy was limited, we failed to observe a significant difference between serum sRAGE concentrations in diabetic patients with retinopathy and concentrations in diabetic patients free of ocular complications. An unpublished observation of Yonekura et al. (2) suggests that patients with retinopathy have significantly lower circulating sRAGE concentrations than patients without retinopathy. We did not observe such a decrease; further studies are therefore required to elucidate the potential relevance of sRAGE measurements in the diagnosis of complications of diabetes mellitus. Blood concentrations of RAGE and of biological variables in patients with type 1 diabetes and healthy controls.1 All values are the mean (SD). Compared with control group: P <0.05; Compared with control group: P <0.01. Blood concentrations of RAGE and of biological variables in patients with type 1 diabetes and healthy controls.1 All values are the mean (SD). Compared with control group: P <0.05; Compared with control group: P <0.01.
No takes yet. Share an insight, caveat, or question.
Challier et al. (2005) conducted a case-control in Type 1 diabetes (n=80). Type 1 diabetes vs. Healthy nondiabetic controls was evaluated on Serum concentrations of soluble receptor for advanced glycation endproducts (sRAGE) (ng/L) (p=<0.001). Patients with type 1 diabetes had higher serum sRAGE concentrations than healthy nondiabetic controls.
Synapse has enriched 10 related papers. Consider them for comparative context: